Evogene Ltd. — Regulatory Filings 2024

May 23, 2024

Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanom false

����� ��"�	2 380
EVOGENE LTD
Corporation no: 512838723	13041
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	23/05/2024
	www.isa.gov.il			www.tase.co.il				Reference:	2024-02-051031	Time of broadcast: 12:07 12:07

---

The corporation scheduled the publication of the report to 23/05/2024 18:00Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onBiomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma

1716380884_a2431499_organized_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: -1	Date of revision of form structure: 07/05/2024
Address: Gad Feinstein St 13, P.O.B 2100 , Rehovot 76121   , Tel: 08-9311900 , Fax: 08-9466724
E-mail address: ofer.haviv@evogene.com   Company site: www.evogene.com
Previous names of reporting entity:
Name of the Signatory: Kofman Guy Position of Signatory in the reporting corporation: Lawyer/ Legal Counsel Name of Employer Company:
Address: Gad Feinstein St. 13 , Rehovot 7638517 Telephone: 08-9311962 Facsimile: 08-9466724 E-mail: guy.kofman@evogene.com 1